Global Pipeline Review & Analysis of Hematological Malignancies

Introduction

The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.

About this report

In this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, the author reports on the hematological cancer pipeline by:

Investigator - Includes 212 investigators and partners
Drug - Includes 237 "active" drugs
Sub-indication - Includes 11 sub-indications
Developmental stage - Includes 8 developmental stages
Compound type - Includes 21 different compounds types
Targeted therapy strategy - Includes 5 different targeted therapy strategies
Target - Includes 97 different protein targets
Signaling pathway - Includes 18 different signaling pathways
All of above "factors" are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each "factor" included in this cutting edge analysis.

Investigator

This report includes 212 investigators and partners from all over the world.

Drug
There are today more than 237 therapeutics for the treatment of hematological cancers, from early preclinical to marketed drugs. Each drug is annotated with a brief drug description.

Sub-indication
The hematological cancer drug pipeline is broken down into 11 sub-indications:
Cancer, leukemia, acute lymphocytic
Cancer, leukemia, acute myelogenous
Cancer, leukemia, chronic lymphocytic
Cancer, leukemia, chronic myelogenous
Cancer, leukemia, general
Cancer, leukemia, hairy cell
Cancer, lymphoma, B-cell
Cancer, lymphoma, general
Cancer, lymphoma, Hodgkin`s
Cancer, lymphoma, non-Hodgkin`s
Cancer, lymphoma, T-cell

Only the highest developmental stage per drug and indication is accounted for.

Developmental Stage

Each sub-indication of a drug is described with its developmental stage:
Preclinical
Clinical Trial
Phase I Clinical Trial
Phase II Clinical Trial
Phase III Clinical Trial
Pre-registration
Registered
Marketed

Compound Type

We have described all 237 drugs in the hematological malignancies pipeline with its corresponding compound type:
Biological
Biological, bacterial cells
Biological, cellular, autologous
Biological, cellular, heterologous
Biological, nucleic acid
Biological, nucleic acid, non-viral vector
Biological, nucleic acid, viral vector
Biological, peptide
Biological, peptide, recombinant
Biological, protein
Biological, protein, antibody
Biological, protein, recombinant
Chemical, semisynthetic
Chemical, synthetic
Chemical, synthetic, isomeric
Chemical, synthetic, nucleic acid
Chemical, synthetic, peptide
Natural product
Natural product, animal
Natural product, bacterial
Natural product, plant

When available, drug compounds are further described with chemical name, CAS number, chemical formula and molecular weight.

Targeted Therapy Strategy

This report categorizes available drugs into 5 major targeted therapy strategies:
1.Angiogenesis
2. Antibody
3. Apoptosis
4. Protein Kinase Inhibitors
5. Vaccines

Target

This analysis includes 97 protein targets, linked to 165 drugs for the treatment of hematological cancers. All protein targets are described by its primary localization, molecular class, molecular function, and biological process:

Primary Localization of Target:
Cell surface
Centrosome
Cytoplasm
Cytosol
Endoplasmic reticulum
Extracellular
Integral to membrane
Lysosome
Mitochondrial membrane
Mitochondrion
Nucleus
Plasma membrane
Secretory granule

Molecular Class of Target:
Adapter molecule
Adhesion molecule
Cell cycle control protein
Cell surface receptor
Chaperone
Cysteine protease
Cytokine
Cytokine receptor
Cytoskeletal protein
DNA methyltransferase
DNA polymerase
DNA repair protein
Enzyme: Deaminase
Enzyme: Decarboxylase
Enzyme: Hydrolase
Enzyme: Ligase
Enzyme: Oxidoreductase
Enzyme: Phosphorylase
Enzyme: Topoisomerase
Enzyme: Transferase
G protein coupled receptor
Growth factor
Integral membrane protein
Ligand
Lipid phosphatase
Membrane bound ligand
MHC complex protein
Nuclear receptor
Receptor tyrosine kinase
Serine protease
Serine/threonine kinase
T cell antigen receptor
Transcription factor
Transcription regulatory protein
Translation regulatory protein
Transport/cargo protein
Tyrosine kinase
Unclassified

Molecular Function of Target:
Carboxy-lyase activity
Cell adhesion molecule activity
Chaperone activity
Cysteine-type peptidase activity
Cytokine activity
Deaminase activity
DNA repair protein
DNA topoisomerase activity
DNA-directed DNA polymerase activity
DNA-methyltransferase activity
G-protein coupled receptor activity
Growth factor activity
Hydrolase activity
Kinase activity
Ligand-dependent nuclear receptor activity
Ligase activity
Lipid phosphatase activity
MHC class I receptor activity
Molecular function unknown
Oxidoreductase activity
Phosphorylase activity
Protein binding
Protein serine/threonine kinase activity
Protein-tyrosine kinase activity
Receptor activity
Receptor binding
Receptor signaling complex scaffold activity
Serine-type peptidase activity
Structural constituent of cytoskeleton
T cell receptor activity
Transcription factor activity
Transcription regulator activity
Transferase activity
Translation regulator activity
Transmembrane receptor activity
Transmembrane receptor protein tyrosine kinase activity
Transporter activity
Unclassified

Biological Process of Target:
Anti-apoptosis
Apoptosis
Cell communication
Cell communication ; Cell surface receptor linked signal transduction
Cell communication ; Signal transduction
Cell communication ; Signal transduction ; Transport
Cell growth and/or maintenance
Enzyme linked receptor protein signaling pathway ; Cellular morphogenesis during differentiation
Immune response
Metabolism
Metabolism; Energy pathways
Protein metabolism
Protein modification
Regulation of cell cycle
Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
Signal transduction
Transport

Signaling Pathway

The 97 available protein targets have been compared with molecular entities in known signaling pathways. This analysis showed the involvement of hematological drugs in at least 18 different signaling pathways:

Alpha6 Beta4 Integrin Signaling Pathway
Androgen Receptor Signaling Pathway
B Cell Receptor Signaling Pathway
EGFR1 Signaling Pathway
ID Signaling Pathway
IL-1 Singaling Pathway
IL-2 Signaling Pathway
IL-3 Signaling Pathway
IL-4 Signaling Pathway
IL-5 Signaling Pathway
IL-6 Signaling Pathway
IL-7 Signaling Pathway
Kit Receptor Signaling Pathway
Notch Signaling Pathway
T Cell Receptor Signaling Pathway
TGF-beta Receptor Signaling Pathway
TNF-alpha Signaling Pathway
Wnt Signaling Pathway SHOW LESS READ MORE >

1 EXECUTIVE SUMMARY

2 CANCER HIGHLIGHTS

TABLE OF CONTENTS
2.1 LIST OF FIGURES
2.2 LIST OF TABLES

3 PLAYERS IN THE FIELD OF HEMATOLOGICAL MALIGNANCIES

4 THE HEMATOLOGICAL CANCER DRUG PIPELINE
4.1 DRUG PIPELINE BY LEUKEMIA
4.2 DRUG PIPELINE BY LYMPHOMA

5 PROTEIN TARGETS IN HEMATOLOGICAL CANCERS
5.1 PURSUED TARGETS IN LEUKEMIA
5.2 PURSUED TARGETS IN LYMPHOMA

6 COMPOUNDS
6.1 OVERVIEW OF COMPOUNDS
6.2 PRESENTATION OF BIOLOGICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.3 PRESENTATION OF CHEMICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.4 PRESENTATION OF NATURAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.5 LEUKEMIA BY COMPOUND TYPES
6.6 LYMPHOMA BY COMPOUND TYPE

7 TARGETED THERAPIES IN HEMATOLOGICAL CANCERS
7.1 TARGETED THERAPIES IN LEUKEMIA
7.2 TARGETED THERPIES IN LYMPHOMA

8 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN
HEMATOLOGICAL CANCERS
8.1 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LEUKEMIA
8.2 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LYMPHOMA

9 PURSUED SIGNALING PATHWAYS IN HEMATOLOGICAL CANCERS
9.1 ALPHA6 BETA4 INTEGRIN SIGNALING PATHWAY
9.1.1 DESCRIPTION OF PATHWAY
9.1.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.2 ANDROGEN RECEPTOR SIGNALING PATHWAY
9.2.1 DESCRIPTION OF PATHWAY
9.2.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.3 B CELL RECEPTOR SIGNALING PATHWAY
9.3.1 DESCRIPTION OF PATHWAY
9.3.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.4 EGFR1 SIGNALING PATHWAY
9.4.1 DESCRIPTION OF PATHWAY
9.4.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.5 ID SIGNALING PATHWAY
9.5.1 DESCRIPTION OF PATHWAY
9.5.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.6 IL-1 SIGNALING PATHWAY
9.6.1 DESCRIPTION OF PATHWAY
9.6.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.7 IL-2 SIGNALING PATHWAY
9.7.1 DESCRIPTION OF PATHWAY
9.7.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.8 IL-3 SIGNALING PATHWAY
9.8.1 DESCRIPTION OF PATHWAY
9.8.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.9 IL-4 SIGNALING PATHWAY
9.9.1 DESCRIPTION OF PATHWAY
9.9.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.10 IL-5 SIGNALING PATHWAY
9.10.1 DESCRIPTION OF PATHWAY
9.10.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.11 IL-6 SIGNALING PATHWAY
9.11.1 DESCRIPTION OF PATHWAY
9.11.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.12 IL-7 SIGNALING PATHWAY
9.12.1 DESCRIPTION OF PATHWAY
9.12.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.13 KIT RECEPTOR SIGNALING PATHWAY
9.13.1 DESCRIPTION OF PATHWAY
9.13.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.14 NOTCH SIGNALING PATHWAY
9.14.1 DESCRIPTION OF PATHWAY
9.14.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.15 T CELL RECEPTOR SIGNALING PATHWAY
9.15.1 DESCRIPTION OF PATHWAY
9.15.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.16 TGF-BETA RECEPTOR SIGNALING PATHWAY
9.16.1 DESCRIPTION OF PATHWAY
9.16.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.17 TNF-ALPHA SIGNALING PATHWAY
9.17.1 DESCRIPTION OF PATHWAY
9.17.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.18 WNT SIGNALING PATHWAY
9.18.1 DESCRIPTION OF PATHWAY
9.18.2 HEMATOLOGICAL CANCER DRUG CANDIDATES

10 BRIEF DRUG DESCRIPTION

11 DISCLAIMER
11.1 LIABILITY
11.2 COMPLETENESS

2.1 List of Figures
Figure 1: The Hematological Cancer Developmental Pipeline
Figure 2: The Leukemia Developmental Pipeline
Figure 3: The Lymphoma Developmental Pipeline
Figure 4: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
Figure 5: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
Figure 6: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Molecular Class of Target
Figure 7: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
Figure 8: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
Figure 9: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Molecular Class of Target
Figure 10: Distribution of Compound Types in the Hematological Malignancies Pipeline
Figure 11: Leukemia Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Typ
Figure 12: Lymphoma Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
Figure 13: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
Figure 14: Lymphoma Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
Figure 15: Angiogenesis – Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 16: Apoptosis – Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 17: Protein Kinase Inhibitors – Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 18: Vaccines – Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 19: Angiogenesis – Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 20: Apoptosis – Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 21: Protein Kinase Inhibitor – Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 22: Vaccines – Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 23: Drug Candidates Involving the Alpha6 Beta4 Integrin Signaling Pathway for the Treatment of Hematological Cancers
Figure 24: Drug Candidates Involving the Androgen Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 25: Drug Candidates Involving the B Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 26: Drug Candidates Involving the EGFR1 Signaling Pathway for the Treatment of Hematological Cancers
Figure 27: Drug Candidates Involving the ID Signaling Pathway for the Treatment of Hematological Cancers
Figure 28: Drug Candidates Involving the IL-1 Signaling Pathway for the Treatment of Hematological Cancers
Figure 29: Drug Candidates Involving the IL-2 Signaling Pathway for the Treatment of Hematological Cancers
Figure 30: Drug Candidates Involving the IL-3 Signaling Pathway for the Treatment of Hematological Cancers
Figure 31: Drug Candidates Involving the IL-4 Signaling Pathway for the Treatment of Hematological Cancer
Figure 32: Drug Candidates Involving the IL-5 Signaling Pathway for the Treatment of Hematological Cancers
Figure 33: Drug Candidates Involving the IL-6 Signaling Pathway for the Treatment of Hematological Cancers
Figure 34 Drug Candidates Involving the IL-7 Signaling Pathway for the Treatment of Hematological Cancers
Figure 35: Drug Candidates Involving the Kit Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 36: Drug Candidates Involving the Notch Signaling Pathway for the Treatment of Hematological Cancers
Figure 37: Drug Candidates Involving the T Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 38: Drug Candidates Involving the TGF-beta Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 39: Drug Candidates Involving the TNF-alpha Signaling Pathway for the Treatment of Hematological Cancers
Figure 40: Drug Candidates Involving the Wnt Signaling Pathway for the Treatment of Hematological Cancers

2.2 List of Tables
Table 1: List of Active Players in the Field of Hematological Malignancies
Table 2: The Leukemia Developmental Pipeline
Table 3: The Lymphoma Developmental Pipeline
Table 4: List of Pursued Protein Targets in Hematological Cancers
Table 5: Hematological Cancer Targets by Investigator and Drug
Table 6: Pursued Targets by Sub-indications of Leukemia
Table 7: Pursued Targets by Sub-indications of Lymphoma
Table 8: Drug Candidates with Its Corresponding Compound Types Listed by Investigator
Table 9: List of Biological Compounds
Table 10: List of Chemical Compounds
Table 11: List of Natural Compounds
Table 12: Developmental Stage and Sub Indication by Compounds Type in Leukemia
Table 13: Developmental Stage and Sub indication bt Compound Types in Lymphoma
Table 14: List of Targeted Therapies in Leukemia100
Table 15: List of Targeted Therapies in Lymphoma
Table 16: Targeted Therapy Strategies Versus Compound Type in Leukemia
Table 17: Targeted Therapy Strategies Versus Compound Types in Lymphoma
Table 18: Targets Linking Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
Table 19: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
Table 20: Targets Linking Drugs to the Androgen Receptor Signaling Pathway
Table 21: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Androgen Receptor Signaling Pathway
Table 22: Targets Linking Drugs to the B Cell Receptor Signaling Pathway
Table 23: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the B Cell Receptor Signaling Pathway
Table 24: Targets Linking Drugs to the EGFR1 Signaling Pathway
Table 25: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the EGFR1 Signaling Pathway
Table 26: Targets Linking Drugs to the ID Signaling Pathway
Table 27: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the ID Signaling Pathway
Table 28: Targets Linking Drugs to the IL-1 Signaling Pathway
Table 29: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-1 Signaling Pathway
Table 30: Targets Linking Drugs to the IL-2 Signaling Pathway
Table 31: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-2 Signaling Pathway
Table 32: Targets Linking Drugs to the IL-3 Signaling Pathway
Table 33: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-3 Signaling Pathway
Table 34: Targets Linking Drugs to the IL-4 Signaling Pathway
Table 35: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-4 Signaling Pathway
Table 36: Targets Linking Drugs to the IL-5 Signaling Pathway
Table 37: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-5 Signaling Pathway
Table 38: Targets Linking Drugs to the IL-6 Signaling Pathway
Table 39: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-6 Signaling Pathway
Table 40: Targets Linking Drugs to the IL-7 Signaling Pathway
Table 41: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-7 Signaling Pathway
Table 42: Targets Linking Drugs to the Kit Receptor Signaling Pathway
Table 43: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Kit Receptor Signaling Pathway
Table 44: Targets Linking Drugs to theNotch Signaling Pathway
Table 45: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Notch Signaling Pathway
Table 46: Targets Linking Drugs to the T Cell Receptor Signaling Pathway
Table 47: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the T Cell Receptor Signaling Pathway
Table 48: Targets Linking Drugs to the TGF-beta Signaling Pathway
Table 49: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TGF-beta Receptor Signaling Pathway
Table 50: Targets Linking Drugs to the TNF-alpha Signaling Pathway
Table 51: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TNF-alpha Signaling Pathway
Table 52: Targets Linking Drugs to the Wnt Signaling Pathway
Table 53: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Wnt Signaling Pathway